Risperidone-induced symptomatic hyperprolactinemia in youth with Schizophrenia: Efficacy and tolerability of cabergoline treatment;Iperprolattinemia sintomatica da risperidone in pazienti giovani affetti da schizofrenia e trattamento con cabergolina: Studio di efficacia e tollerabilità

Clinica Terapeutica

Volumn 158, Issue 2, 2007, Pages 121-126

  Pollice, R ^a   Di Giovambattista, E ^a   Tomassini, A ^a   Di Pucchio, A ^a   Mazza, M ^a   Di Michele, V ^a   Roncone, R ^a   Casacchia, Massimo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cabergoline; Hyperprolactinemia; Risperidone; Schizophrenia; Side effects; Youths

Indexed keywords

CABERGOLINE; PROLACTIN; RISPERIDONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MALE; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; RISPERIDONE; SCHIZOPHRENIA;

EID: 34248167046     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363(9426):2063-72
2. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60 (suppl. 23):5-9
3. Larsen TK, Friis S, Haahr, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand 2001; 103(5):321-2
4. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51(1):17-29
5. Marshall M, Lockwood A. Early Intervention for psychosis. Cochrane Database Syst Rev 2004; (2):CD004718
6. Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162(10):1785-804
7. Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31(3):705-22
8. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65(8):1113-38
9. Ruhrmann S, Schultze-Lutter F, Maier W, et al. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 2005; 20(1):1-6
10. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35:75-86
11. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4):514-20
12. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002; 3(10):1381-91
13. Kleinberg D, Davis J, De Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57-61
14. Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005; 15(6):893-900
15. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002; 14(3):163-73
16. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005; 66(6):761-7
17. David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, haloperidol on plasma prolactine levels in patients with schizophrenia. Clin Ther 2000; 22(9):1085-96
18. Rourke C, Starr KR, Reavill C, et al. Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data. Psychopharmacol 2006; 184(1):107-14
19. Chung YC, Eun HB. Hyperprolactinaemia induced by risperidone. Int J Neuropsychopharmacol 1998; 1(1):93-4
20. Kearns AE, Goff DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract 2000; 6 (6): 425-9
21. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. Child Adolesc Psychopharmacol 2001; 11(4):435-40
22. Brunelleschi S, Zeppegno P, Risso F, et al. Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol Res 2003; 48:405-9
23. Wieck A, Haddad P. Hyperprolactinemia caused by antipsychotic drugs. BMJ 2002; 324:250-2
24. Tollin SR. Use of the dopamine-agonists bromocriptine and cabergoline in management of risperidone induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23(11):765-70
25. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 2004; 64(18):2125-41
26. Bonuccelli U. Comparing dopamine-agonists in Parkinson's disease. Curr Opin Neurol 2003; 16(1):S13-9
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC American Psychiatric Press, 1994
28. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-76
30. Rack MJ, Baran AS, Richert AC, et al. Cardiopulmonary complications of ergot-derivative dopamine agonists. J Clin Psychiatry 2004; 65(2):187-90
31. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2002; 11(4):435-40
32. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65(2):187-90
33. Yung R, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic tretment of patients with schizophrenia carry ng DRD2 A1 allele. Br J Psychiatry 2004; 185:147-51
34. Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy with microprolactinomas. Clin Endocrinol (Oxf) 2005; 63(1):26-31
35. Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004, 89(4):1704-11
36. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescent. J Clin Psychiatry 2005; 66(7):29-40